L-selectin in inflammation, infection and immunity

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 3, 2005, Pages 213-220

  Raffler, Nikolai A ^a   Rivera Nieves, Jesús ^a   Ley, Klaus ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; APTAMER; ASELIZUMAB; BIMOSIAMOSE; BMS 190394; CY 1503; CYLEXIN; DREG 200; DREG 55; EL 246; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FUCOIDIN; L SELECTIN; LAMI 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DREG 200; MONOCLONAL ANTIBODY DREG 55; MONOCLONAL ANTIBODY LAMI 3; OC 229648; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PLACEBO; SIALOPROTEIN; SMART; TS 1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BINDING AFFINITY; CANCER; CELLULAR IMMUNITY; CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE ADHERENCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE;

EID: 27144446771     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.08.012     Document Type: Review

References (78)

1. K. Ley and G.S. Kansas Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation Nat. Rev. Immunol. 4 2004 325-335
2. E.L. Berg et al. L-selectin-mediated lymphocyte rolling on MAdCAM-1 Nature 366 1993 695-698
3. M. Sperandio et al. P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules J. Exp. Med. 197 2003 1355-1363
4. S.D. Rosen Ligands for L-selectin: Homing, inflammation and beyond Annu. Rev. Immunol. 22 2004 129-156
5. C.C. Chao et al. Mechanisms of L-selectin regulation by activated T cells J. Immunol. 159 1997 1686-1694
6. F. Sallusto et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 401 1999 708-712
7. D.L. Farber and M. Ahmadzadeh Dissecting the complexity of the memory T cell response Immunol. Res. 25 2002 247-259
8. H. Unsoeld and H. Pircher Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7 J. Virol. 79 2005 4510-4513
9. M. Ahmadzadeh et al. Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells J. Immunol. 166 2001 926-935
10. A.D. Roberts et al. Differential contributions of central and effector memory T cells to recall responses J. Exp. Med. 202 2005 123-133
11. E.J. Wherry et al. Lineage relationship and protective immunity of memory CD8 T cell subsets Nat. Immunol. 4 2003 225-234
12. V. Appay et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections Nat. Med. 8 2002 379-385
13. T.H. Rainer L -selectin in health and disease Resuscitation 52 2002 127-141
14. M.L. Arbones et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice Immunity 1 1994 247-260
15. D.A. Steeber et al. Lymphocyte migration in L-selectin-deficient mice. Altered subset migration and aging of the immune system J. Immunol. 157 1996 1096-1106
16. D.A. Steeber et al. Efficient lymphocyte migration across high endothelial venules of mouse Peyer's patches requires overlapping expression of L-selectin and beta7 integrin J. Immunol. 161 1998 6638-6647
17. J. Xu et al. Impaired primary T cell responses in L-selectin-deficient mice J. Exp. Med. 183 1996 589-598
18. T.F. Tedder et al. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites J. Exp. Med. 181 1995 2259-2264
19. K. Ley et al. Sequential contribution of L - and P-selectin to leukocyte rolling in vivo J. Exp. Med. 181 1995 669-675
20. U. Jung et al. Gene-targeted mice reveal importance of L-selectin-dependent rolling for neutrophil adhesion Am. J. Physiol. 274 1998 H1785-H1791
21. C. Zaph et al. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites Nat. Med. 10 2004 1104-1110
22. J. Rivera-Nieves et al. L -selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine J. Immunol. 174 2005 2343-2352
23. S.R. Targan et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N. Engl. J. Med. 337 1997 1029-1035
24. S.R. Reese et al. L -selectin and alpha 4 beta 7 integrin, but not ICAM-1, regulate lymphocyte distribution in gut-associated lymphoid tissue of mice Surgery 137 2005 209-215
25. J. Mudter et al. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: Insights into the regulatory role of interleukin-6 on apoptosis Pathobiology 70 2002 170-176
26. M.F. Neurath et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease J. Exp. Med. 195 2002 1129-1143
27. B. Weigmann et al. A critical regulatory role of leucin zipper transcription factor c-Maf in Th1-mediated experimental colitis J. Immunol. 173 2004 3446-3455
28. - -CD4+ tumor-reactive T cells Laryngoscope 110 2000 1648-1654
29. S.L. Meijer et al. Reduced L -selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine Cell Immunol. 227 2004 93-102
30. E. Aydt and G. Wolff Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma Pathobiology 70 2003 297-301
31. S.J. Romano Selectin antagonists: Therapeutic potential in asthma and COPD Treat. Respir. Med. 4 2005 85-94
32. M.P. Schon et al. Targeting selectin functions in the therapy of psoriasis Curr. Drug Targets Inflamm. Allergy 3 2004 163-168
33. D.M. Lewinsohn et al. Leukocyte-endothelial cell recognition: Evidence of a common molecular mechanism shared by neutrophils, lymphocytes, and other leukocytes J. Immunol. 138 1987 4313-4321
34. M.A. Jutila et al. Function and regulation of the neutrophil MEL-14 antigen in vivo: Comparison with LFA-1 and MAC-1 J. Immunol. 143 1989 3318-3324
35. P. Pizcueta and F.W. Luscinskas Monoclonal antibody blockade of L-selectin inhibits mononuclear leukocyte recruitment to inflammatory sites in vivo Am. J. Pathol. 145 1994 461-469
36. J. Katahira et al. Role of anti-L-selectin antibody in burn and smoke inhalation injury in sheep Am. J. Physiol. Lung Cell. Mol. Physiol. 283 2002 L1043-L1050
37. D. Mihelcic et al. Inhibition of leukocyte L-selectin function with a monoclonal antibody attenuates reperfusion injury to the rabbit ear Blood 84 1994 2322-2328
38. C. Ramamoorthy et al. Blocking L-selectin function attenuates reperfusion injury following hemorrhagic shock in rabbits Am. J. Physiol. 271 1996 H1871-H1877
39. R. Winn et al. Endothelial and leukocyte adhesion molecules in inflammation and disease Blood Coagul. Fibrinolysis 9 Suppl. 2 1998 S17-S23
40. P.C. Ridings et al. A dual-binding antibody to E - and L-selectin attenuates sepsis-induced lung injury Am. J. Respir. Crit. Care Med. 152 1995 247-253
41. A. Seekamp et al. The effect of anti- L-selectin (EL-246) on remote lung injury after infrarenal ischemia/reperfusion Shock 7 1997 447-454
42. Y.M. Carter et al. Intracoronary E-/L-selectin blockade reduces neutrophil infiltration in heart transplantation Ann. Thorac. Surg. 74 2002 2064-2070
43. M.S. Carraway et al. Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons Am. J. Respir. Crit. Care Med. 157 1998 938-949
44. M. Buerke et al. Humanized monoclonal antibody DREG-200 directed against L-selectin protects in feline myocardial reperfusion injury J. Pharmacol. Exp. Ther. 271 1994 134-142
45. A. Seekamp et al. The effect of anti- L-selectin (aselizumab) in multiple traumatized patients - results of a Phase II clinical trial Crit. Care Med. 32 2004 2021-2028
46. B.J. Hicke et al. DNA aptamers block L -selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice J. Clin. Invest. 98 1996 2688-2692
47. D. O'Connell et al. Calcium-dependent oligonucleotide antagonists specific for L-selectin Proc. Natl. Acad. Sci. U S A 93 1996 5883-5887
48. S. Hemmerich et al. Strategies for drug discovery by targeting sulfation pathways Drug Discov. Today 9 2004 967-975
49. K.T. Han et al. Sialyl Lewis(x) oligosaccharide reduces ischemia-reperfusion injury in the rabbit ear J. Immunol. 155 1995 4011-4015
50. M. Buerke et al. Sialyl LewisX-containing oligosaccharide attenuates myocardial reperfusion injury in cats J. Clin. Invest. 93 1994 1140-1148
51. D.J. Lefer et al. A novel sialyl LewisX analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion Circulation 90 1994 2390-2401
52. P.C. Ridings et al. Protective role of synthetic sialylated oligosaccharide in sepsis-induced acute lung injury J. Appl. Physiol. 82 1997 644-651
53. M. Shimaoka et al. Fucoidin, a potent inhibitor of leukocyte rolling, prevents neutrophil influx into phorbol-ester-induced inflammatory sites in rabbit lungs Am. J. Respir. Crit. Care Med. 153 1996 307-311
54. K. Ley et al. Shear-dependent inhibition of granulocyte adhesion to cultured endothelium by dextran sulfate Blood 73 1989 1324-1330
55. A. Kumar et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model Circulation 99 1999 1363-1369
56. A.E. Hicks et al. Recombinant P-selectin glycoprotein ligand-1 directly inhibits leukocyte rolling by all 3 selectins in vivo: Complete inhibition of rolling is not required for anti-inflammatory effect Blood 101 2003 3249-3256
57. R. Hayward et al. Recombinant soluble P -selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats Cardiovasc. Res. 41 1999 65-76
58. G. Todderud et al. BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions J. Pharmacol. Exp. Ther. 282 1997 1298-1304
59. S.J. Romano et al. D.H. Slee Targeting selectins for the treatment of respiratory diseases Curr. Opin. Investig. Drugs 2 2001 907-913
60. D.H. Slee et al. Development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with anti-inflammatory activity J. Med. Chem. 44 2001 2094-2107
61. T.P. Kogan et al. Novel synthetic inhibitors of selectin-mediated cell adhesion: Synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha- d -mannopyranosyloxy)phenyl]hexane (TBC1269) J. Med. Chem. 41 1998 1099-1111
62. J.M. Palma-Vargas et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion J. Am. Coll. Surg. 185 1997 365-372
63. P.C. Avila et al. Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses Clin. Exp. Allergy 34 2004 77-84
64. A.E. Hicks et al. The anti-inflammatory effects of a selectin ligand mimetic, TBC-1269, are not a result of competitive inhibition of leukocyte rolling in vivo J. Leukoc. Biol. 77 2005 59-66
65. R. Langer et al. Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines J. Am. Soc. Nephrol. 15 2004 2893-2901
66. K.M. Beeh et al. Influence of inhaled Bimosiamose (TBC1269), a synthetic pan-selectin antagonist, on the allergen-induced late asthmatic response (LAR) in patients with mild allergic asthma Am. J. Respir. Crit. Care Med. 169 2004 A321
67. E. Lin et al. Selectin neutralization: Does it make biological sense? Crit. Care Med. 27 1999 2050-2053
68. U. Jung and K. Ley Mice lacking two or all three selectins demonstrate overlapping and distinct functions for each selectin J. Immunol. 162 1999 6755-6762
69. J. Alper Searching for medicine's sweet spot Science 291 2001 2338-2343
70. R.F. Service After the fall Science 291 2001 2340-2341
71. I.Y. Park et al. Cylexin: A P-selectin inhibitor prolongs heart allograft survival in hypersensitized rat recipients Transplant. Proc. 30 1998 2927-2928
72. K.M. Kerr et al. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy Am. J. Respir. Crit. Care Med. 162 2000 14-20
73. Thios Pharmaceuticals (2005) Thios Pharmaceuticals licences clinical compound rPSGL-Ig from Wyeth (http://www.thiospharm.com/news/2004/01-07-04.html)
74. S.P. Khor et al. Pharmacokinetics, pharmacodynamics, allometry and dose selection of rPSGL-Ig for Phase I trial J. Pharmacol. Exp. Ther. 293 2000 618-624
75. Revotar Biopharmaceuticals AG (2005) Revotar Biopharmaceuticals AG announces first positive results with a new topical formulation of a small molecule selectin antagonist in psoriasis. (http://www.revotar.de/pdf/topical_press_release.pdf)
76. R. Anaya-Prado et al. Multiple selectin blockade with a small-molecule selectin inhibitor does not affect survival after a second inflammatory challenge with nonlethal LPS J. Invest. Surg. 15 2002 171-180
77. Protein Design Labs (1999) Protein design labs announces Phase II trial of SMART anti- L -selectin antibody (http://www.pdl.com/index.cfm?navId=382)
78. M.S. Co et al. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin Immunotechnol. 4 1999 253-266